Resiliency Through Azithromycin for Children (REACH), Côte d'Ivoire
Status:
Completed
Trial end date:
2021-01-31
Target enrollment:
Participant gender:
Summary
The aim of the study is to gather preliminary evidence on the operational feasibility and
acceptability of integrating bi-annual mass drug administration (MDA) of single-dose
azithromycin for children ages 1 to 11 months in high child mortality settings in Côte. The
cross-sectional study will be carried out in conjunction with a single trachoma MDA in
selected villages within one health district. Data on feasibility and acceptability will be
collected through three main activities:
1. Analyses of existing routine monitoring, process, and adverse drug reaction data from
the trachoma MDA platform into which the pilot activities are being integrated
2. A cross-sectional, post-MDA coverage survey
3. Qualitative data collection among targeting parents or primary caregivers of children
ages 1 to 11 months in the pilot districts, and district-level MDA implementers,
regarding the proposed azithromycin program.
Phase:
N/A
Details
Lead Sponsor:
FHI 360
Collaborators:
Côte d'Ivoire National Program for the Fight Against Neglected Tropical Diseases National Program for the Fight Against Neglected Tropical Diseases, Côte d'Ivoire